,address1,address2,city,state,zip,country,phone,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,pegRatio,lastSplitFactor,lastSplitDate,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,debtToEquity,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,4224 Campus Point Court,Suite 210,San Diego,CA,92121,United States,858 202 6300,https://www.regulusrx.com,Biotechnology,Healthcare,"Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.",30,"{'maxAge': 1, 'name': 'Mr. Joseph P. Hagan M.B.A.', 'age': 53, 'title': 'CEO & Director', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 920728, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.7,1.7,1.63,1.7,1.7,1.7,1.63,1.7,0.0,1.64419,-0.8947369,27943,27943,32101,105730,105730,1.6,1.71,800,3100,33123650,0.76,2.18,1.459,1.37615,0.0,0.0,USD,2189583,0.0,15584841,19484500,186977,216264,1690761600,1693440000,0.0095999995,0.03405,0.54469,10.13,0.0125,1.745,0.97421205,1672444800,1703980800,1688083200,-28498000,-1.73,-1.9,-0.03,1:12,1538611200,-0.075,NCM,EQUITY,RGLS,RGLS,Regulus Therapeutics Inc.,Regulus Therapeutics Inc.,1349789400,America/New_York,EDT,-14400000,1.7,9.0,2.0,5.5,5.5,2.0,buy,4,37263000,1.912,-29019000,6324000,4.529,5.026,18.602,-0.37238997,-0.74637,-18410000,-17523376,-27352000,0.0,0.0,0.0,USD,
1,4224 Campus Point Court,Suite 210,San Diego,CA,92121,United States,858 202 6300,https://www.regulusrx.com,Biotechnology,Healthcare,"Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.",30,"{'maxAge': 1, 'name': 'Ms. Crispina  Calsada CPA', 'age': 52, 'title': 'Chief Financial Officer', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 500866, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.7,1.7,1.63,1.7,1.7,1.7,1.63,1.7,0.0,1.64419,-0.8947369,27943,27943,32101,105730,105730,1.6,1.71,800,3100,33123650,0.76,2.18,1.459,1.37615,0.0,0.0,USD,2189583,0.0,15584841,19484500,186977,216264,1690761600,1693440000,0.0095999995,0.03405,0.54469,10.13,0.0125,1.745,0.97421205,1672444800,1703980800,1688083200,-28498000,-1.73,-1.9,-0.03,1:12,1538611200,-0.075,NCM,EQUITY,RGLS,RGLS,Regulus Therapeutics Inc.,Regulus Therapeutics Inc.,1349789400,America/New_York,EDT,-14400000,1.7,9.0,2.0,5.5,5.5,2.0,buy,4,37263000,1.912,-29019000,6324000,4.529,5.026,18.602,-0.37238997,-0.74637,-18410000,-17523376,-27352000,0.0,0.0,0.0,USD,
2,4224 Campus Point Court,Suite 210,San Diego,CA,92121,United States,858 202 6300,https://www.regulusrx.com,Biotechnology,Healthcare,"Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.",30,"{'maxAge': 1, 'name': 'Mr. Christopher Ray Aker J.D.', 'age': 61, 'title': 'Sr. VP, Gen. Counsel & Corp. Sec.', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 524790, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.7,1.7,1.63,1.7,1.7,1.7,1.63,1.7,0.0,1.64419,-0.8947369,27943,27943,32101,105730,105730,1.6,1.71,800,3100,33123650,0.76,2.18,1.459,1.37615,0.0,0.0,USD,2189583,0.0,15584841,19484500,186977,216264,1690761600,1693440000,0.0095999995,0.03405,0.54469,10.13,0.0125,1.745,0.97421205,1672444800,1703980800,1688083200,-28498000,-1.73,-1.9,-0.03,1:12,1538611200,-0.075,NCM,EQUITY,RGLS,RGLS,Regulus Therapeutics Inc.,Regulus Therapeutics Inc.,1349789400,America/New_York,EDT,-14400000,1.7,9.0,2.0,5.5,5.5,2.0,buy,4,37263000,1.912,-29019000,6324000,4.529,5.026,18.602,-0.37238997,-0.74637,-18410000,-17523376,-27352000,0.0,0.0,0.0,USD,
3,4224 Campus Point Court,Suite 210,San Diego,CA,92121,United States,858 202 6300,https://www.regulusrx.com,Biotechnology,Healthcare,"Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.",30,"{'maxAge': 1, 'name': 'Dr. Preston S. Klassen M.D., M.H.S.', 'age': 53, 'title': 'Pres and Head of R&D', 'yearBorn': 1969, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.7,1.7,1.63,1.7,1.7,1.7,1.63,1.7,0.0,1.64419,-0.8947369,27943,27943,32101,105730,105730,1.6,1.71,800,3100,33123650,0.76,2.18,1.459,1.37615,0.0,0.0,USD,2189583,0.0,15584841,19484500,186977,216264,1690761600,1693440000,0.0095999995,0.03405,0.54469,10.13,0.0125,1.745,0.97421205,1672444800,1703980800,1688083200,-28498000,-1.73,-1.9,-0.03,1:12,1538611200,-0.075,NCM,EQUITY,RGLS,RGLS,Regulus Therapeutics Inc.,Regulus Therapeutics Inc.,1349789400,America/New_York,EDT,-14400000,1.7,9.0,2.0,5.5,5.5,2.0,buy,4,37263000,1.912,-29019000,6324000,4.529,5.026,18.602,-0.37238997,-0.74637,-18410000,-17523376,-27352000,0.0,0.0,0.0,USD,
4,4224 Campus Point Court,Suite 210,San Diego,CA,92121,United States,858 202 6300,https://www.regulusrx.com,Biotechnology,Healthcare,"Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.",30,"{'maxAge': 1, 'name': 'Mr. Daniel J. Penksa', 'age': 36, 'title': 'Exec. Director of Fin. & Controller', 'yearBorn': 1986, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.7,1.7,1.63,1.7,1.7,1.7,1.63,1.7,0.0,1.64419,-0.8947369,27943,27943,32101,105730,105730,1.6,1.71,800,3100,33123650,0.76,2.18,1.459,1.37615,0.0,0.0,USD,2189583,0.0,15584841,19484500,186977,216264,1690761600,1693440000,0.0095999995,0.03405,0.54469,10.13,0.0125,1.745,0.97421205,1672444800,1703980800,1688083200,-28498000,-1.73,-1.9,-0.03,1:12,1538611200,-0.075,NCM,EQUITY,RGLS,RGLS,Regulus Therapeutics Inc.,Regulus Therapeutics Inc.,1349789400,America/New_York,EDT,-14400000,1.7,9.0,2.0,5.5,5.5,2.0,buy,4,37263000,1.912,-29019000,6324000,4.529,5.026,18.602,-0.37238997,-0.74637,-18410000,-17523376,-27352000,0.0,0.0,0.0,USD,
5,4224 Campus Point Court,Suite 210,San Diego,CA,92121,United States,858 202 6300,https://www.regulusrx.com,Biotechnology,Healthcare,"Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.",30,"{'maxAge': 1, 'name': 'Dr. Claire Susan Padgett M.S., M.T., Ph.D.', 'title': 'Sr. VP of Clinical Operations', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.7,1.7,1.63,1.7,1.7,1.7,1.63,1.7,0.0,1.64419,-0.8947369,27943,27943,32101,105730,105730,1.6,1.71,800,3100,33123650,0.76,2.18,1.459,1.37615,0.0,0.0,USD,2189583,0.0,15584841,19484500,186977,216264,1690761600,1693440000,0.0095999995,0.03405,0.54469,10.13,0.0125,1.745,0.97421205,1672444800,1703980800,1688083200,-28498000,-1.73,-1.9,-0.03,1:12,1538611200,-0.075,NCM,EQUITY,RGLS,RGLS,Regulus Therapeutics Inc.,Regulus Therapeutics Inc.,1349789400,America/New_York,EDT,-14400000,1.7,9.0,2.0,5.5,5.5,2.0,buy,4,37263000,1.912,-29019000,6324000,4.529,5.026,18.602,-0.37238997,-0.74637,-18410000,-17523376,-27352000,0.0,0.0,0.0,USD,
6,4224 Campus Point Court,Suite 210,San Diego,CA,92121,United States,858 202 6300,https://www.regulusrx.com,Biotechnology,Healthcare,"Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.",30,"{'maxAge': 1, 'name': 'Dr. Rekha  Garg M.D., M.S.', 'title': 'Sr. VP of Clinical Devel. & Regulatory', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.7,1.7,1.63,1.7,1.7,1.7,1.63,1.7,0.0,1.64419,-0.8947369,27943,27943,32101,105730,105730,1.6,1.71,800,3100,33123650,0.76,2.18,1.459,1.37615,0.0,0.0,USD,2189583,0.0,15584841,19484500,186977,216264,1690761600,1693440000,0.0095999995,0.03405,0.54469,10.13,0.0125,1.745,0.97421205,1672444800,1703980800,1688083200,-28498000,-1.73,-1.9,-0.03,1:12,1538611200,-0.075,NCM,EQUITY,RGLS,RGLS,Regulus Therapeutics Inc.,Regulus Therapeutics Inc.,1349789400,America/New_York,EDT,-14400000,1.7,9.0,2.0,5.5,5.5,2.0,buy,4,37263000,1.912,-29019000,6324000,4.529,5.026,18.602,-0.37238997,-0.74637,-18410000,-17523376,-27352000,0.0,0.0,0.0,USD,
